Internal Medicine
Partner With Us
Advertisement
Conexiant chevron_right Internal Medicine chevron_right Does Combination Therapy Improve Albuminuria
Conference News From the Journals 62nd European Renal Association (ERA) Congress

Does Combination Therapy Improve Albuminuria?

Finerenone plus empagliflozin reduced urinary albumin-to-creatinine ratio by 29% to 32% more than either drug alone in patients with chronic kidney disease and type 2 diabetes.

Conexiant
Full Article Summary Notecard
  1. Combination therapy with finerenone and empagliflozin resulted in significantly greater reductions in UACR.
  2. The safety profile showed no unexpected signals, and hyperkalemia was reported to a greater extent in the combination group.
  3. A 30% reduction in UACR is associated with a lower risk of adverse kidney outcomes.
  4. The trial included patients with chronic kidney disease, albuminuria, and type 2 diabetes.
  5. Researchers noted that most of the reduction in UACR occurred within 4 weeks after therapy initiation.

Daily News

Stay up to date with the latest clinical headlines and other information tailored to your specialty.